Tagged with ISPOR

Global Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched access and affordability issues.   Healthcare can only be widely effective if most patients can access and afford it. Yet,…

Global HEOR is transforming healthcare decision-making by evaluating treatment costs, patient quality of life, and overall value, helping stakeholders make informed choices. ISPOR’s new “HEOR Explained” website simplifies these complex concepts to promote wider understanding and application of real-world evidence and ultimately drive more effective and sustainable healthcare.   In today’s…

Global Scott D. Ramsey of the Fred Hutchinson Cancer Center discusses the trend driving pharmaceutical companies to reorganize or eliminate their health economics and outcomes research (HEOR) groups. The original version of this article was featured in the September/October edition of ISPOR’s Value & Outcomes Spotlight magazine.   Last spring, I had…

Global Against the backdrop of a global push to make healthcare more accessible and affordable, ISPOR CEO and executive director Rob Abbott introduces the organisation’s 2030 strategy, focused on achieving health system sustainability around the world. The original version of this article was featured in the July/August 2024 edition of ISPOR’s Value…

Global Recently appointed ISPOR President Eberechukwu Onukwugha, PhD, lays out her inclusive vision for the organisation’s future, championing health economic and outcomes research excellence and innovation that works for all. The original version of this article featured in the July/August edition of ISPOR’s Value & Outcomes Spotlight magazine.   As I…

Global Writing in the June 2024 edition of ISPOR’s Value in Health journal, Nancy J. Devlin, PhD, Michael F. Drummond, MCom, DPhil, and C. Daniel Mullins, PhD look back on the history of QALYs in cost-effectiveness analysis and policy decision making, and why the backlash against QALYs in the United States…

Global ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), and PharmaBoardroom’s content partner, continues to monitor healthcare trends and conduct horizon scanning around the world. The “ISPOR 2024-2025 Top 10 HEOR Trends” marks the fifth publication of the Society’s biennial report, which is based on input from its members…

Global Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of providing quality treatments and services to patients while ensuring that their money is well spent. At the forefront of helping…

Czech Republic Tomáš Dolezal, president of the International Society for Pharmacoeconomics and Outcomes (ISPOR) Czech Regional Chapter and director of the Institute of Health Economics and Technology Assessment (iHETA), gives an overview of the missions and goals of these two institutes and the pivotal role of health technology assessment (HTA) in the…